Samantha Du's Zai Lab sets its ambitions sky high, looking to raise $750M to fuel its licensing business model

Kyle Blankenship

Looking to capitalize on a bustling Chinese drug market, upstart biotechs like Samantha Du’s Zai Lab have made a killing in-licensing foreign molecules as well …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Samantha Du's Zai Lab sets its ambitions sky high, looking to raise $750M to fuel its licensing business model

Kyle Blankenship

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Biotech seed rounds sink to lowest level in years as industry slump drags on

US drugs rely heavily on ingredients made overseas, new report shows

Pharma's wins and losses in Trump's sprawling executive order on drug prices

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Saman­tha Du's Zai Lab sets its am­bi­tions sky high, look­ing to raise $750M to fu­el its li­cens­ing busi­ness mod­el

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Samantha Du's Zai Lab sets its ambitions sky high, looking to raise $750M to fuel its licensing business model